安进-阿斯利康肺癌联合用药在后期临床试验中显著提升生存率

格隆汇09-09 10:39

安进的靶向免疫疗法药物Imdelltra与阿斯利康的抗癌药物Imfinzi联合用药，在一项后期临床试验中显著提高了广泛期小细胞肺癌患者的总生存期。该试验测试了该联合疗法作为维持治疗方案，与单独使用Imfinzi治疗标准诱导治疗后病情未进展的患者相比的疗效。除总生存期外，该联合疗法还提高了无进展生存期和缓解率。未发现新的安全性问题。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2666309213?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-09-09 10:39","share_image_url":"https://static.laohu8.com/6b8fa6424aebe95f6781d04ef17a1852","id":"2666309213","market":"us","top_or_hot":-1,"title":"安进-阿斯利康肺癌联合用药在后期临床试验中显著提升生存率","media":"格隆汇","content":"<html><body>安进的靶向免疫疗法药物Imdelltra与阿斯利康的抗癌药物Imfinzi联合用药，在一项后期临床试验中显著提高了广泛期小细胞肺癌患者的总生存期。该试验测试了该联合疗法作为维持治疗方案，与单独使用Imfinzi治疗标准诱导治疗后病情未进展的患者相比的疗效。除总生存期外，该联合疗法还提高了无进展生存期和缓解率。未发现新的安全性问题。</body></html>","source":"live_gelonghui","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>安进-阿斯利康肺癌联合用药在后期临床试验中显著提升生存率</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n安进-阿斯利康肺癌联合用药在后期临床试验中显著提升生存率\n</h2>\n\n<h4 class=\"meta\">\n\n</h4>\n\n</header>\n<article>\n<html><body>安进的靶向免疫疗法药物Imdelltra与阿斯利康的抗癌药物Imfinzi联合用药，在一项后期临床试验中显著提高了广泛期小细胞肺癌患者的总生存期。该试验测试了该联合疗法作为维持治疗方案，与单独使用Imfinzi治疗标准诱导治疗后病情未进展的患者相比的疗效。除总生存期外，该联合疗法还提高了无进展生存期和缓解率。未发现新的安全性问题。</body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.gelonghui.com/rss/live/live.xml\">格隆汇</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999001440.SGD","symbol_name":"United Global Dividend Equity Fund A SGD Dist","start_time":0,"source_url":"https://www.gelonghui.com/rss/live/live.xml","article_id":"2666309213","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2666309213","pubTimestamp":1788921579,"columns":[],"sourceInfo":{"source_id":"live_gelonghui","name":"格隆汇"},"weMediaInfo":null,"summary":"安进的靶向免疫疗法药物Imdelltra与阿斯利康的抗癌药物Imfinzi联合用药，在一项后期临床试验中显著提高了广泛期小细胞肺癌患者的总生存期。该试验测试了该联合疗法作为维持治疗方案，与单独使用Im","collect":0,"end_time":0,"defaultTopTitle":"gelonghui.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","BK4581":"高盛持仓","PJP":"INVESCO PHARMACEUTICALS ETF","TBXU":"Direxion Daily Biotech Top 5 Bull 2X ETF","AMGN":"安进","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BIB":"Ultra纳斯达克生物科","BK4534":"瑞士信贷持仓","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4139":"生物科技","PSYK":"PSYK ETF","BK4588":"碎股","PBE":"INVESCO BIOTECHNOLOGY & GENOME ETF","BK4533":"AQR资本管理(全球第二大对冲基金)","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","BMED":"iShares Health Innovation Active ETF","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4566":"资本集团","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","IBB":"生物科技指数ETF-iShares Nasdaq","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF","IBBQ":"Invesco Nasdaq Biotechnology ETF","BK4599":"减肥药","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","MDTX":"Corgi MediaTek 2x Daily ETF","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","LU0122379950.USD":"贝莱德世界健康科学A2","BBH":"VanEck Biotech ETF","LU0058720904.USD":"联博国际健康护理基金A","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD"},"translate_title":"Amgen-AstraZeneca lung cancer combination drug significantly improves survival rate in later clinical trials","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TBXU":0.6,"BBH":0.6,"IBBJ":1.5,"PBE":0.6,"IBBQ":1.5,"PSYK":1.5,"MDTX":1.5,"BMED":1.5,"AMGN":1.5,"IBB":0.6,"PJP":0.6,"BIB":0.6},"content_text":"安进的靶向免疫疗法药物Imdelltra与阿斯利康的抗癌药物Imfinzi联合用药，在一项后期临床试验中显著提高了广泛期小细胞肺癌患者的总生存期。该试验测试了该联合疗法作为维持治疗方案，与单独使用Imfinzi治疗标准诱导治疗后病情未进展的患者相比的疗效。除总生存期外，该联合疗法还提高了无进展生存期和缓解率。未发现新的安全性问题。","kind":"live","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2666309213","isCrawlerRequest":true}